Möchten Sie immer auf dem neuesten Stand bleiben?

Aptose Biosciences Announces Results of Special Shareholders Meeting; Announces Receipt of Final Court Approval of Plan of Arrangement; Reports Year End 20

ZyVersa Therapeutics, a biopharma company developing first-in-class drugs for renal and inflammatory diseases, reports 2025 financial results.

Rinzimetostat 400 mg once daily selected as RP3D in combination with darolutamide for Himalayas-1 global Phase 3 registrational trial in post-abiraterone mCRPC, with initiation expected in 1H 2026 At...

Earnings Call Webcast to Discuss 2025 Fourth Quarter and Full Year Financial Results Scheduled to Post to Corporate Website by Thursday, April 02, 2026 NEW YORK, March 31, 2026 (GLOBE NEWSWIRE) --...

HSINCHU, Taiwan, March 31, 2026 (GLOBE NEWSWIRE) -- As a global leader in display technologies and solutions, AUO leverages group‑wide strengths to continuously advance deployment across vertical...

Parandatud kuupäev lauses: Üldkoosolekul hääleõiguslike aktsionäride nimekiri fikseeritakse seitse päeva enne üld­koosoleku toimumist, s.o 16. aprillil 2026 Nasdaq CSD Eesti arveldussüsteemi tööpäeva...

Date correction in the following sentence: The list of shareholders entitled to vote at the General Meeting will be established 7 days prior to the General Meeting, i.e., as of 16 April 2026 at the...

TNX-4800 is a long-acting anti-Borrelia burgdorferi OspA human monoclonal antibody in development as a single-dose Lyme prophylactic Phase 1 study of TNX-4800 demonstrated safety, tolerability, and...

New York City, NY, March 31, 2026 (GLOBE NEWSWIRE) -- There are multiple promotions available across Bitcoin casinos today, but many of them still come with unclear terms or slow...

Incorporating Veins 006b and 013 into the production profile has the potential to materially increase the daily mined tonnage from Rowan